Cargando…

Integrated T cell cytometry metrics for immune-monitoring applications in immunotherapy clinical trials

Mass cytometry, or cytometry by TOF (CyTOF), provides a robust means of determining protein-level measurements of more than 40 markers simultaneously. While the functional states of immune cells occur along continuous phenotypic transitions, cytometric studies surveying cell phenotypes often rely on...

Descripción completa

Detalles Bibliográficos
Autores principales: Sidiropoulos, Dimitrios N., Stein-O’Brien, Genevieve L., Danilova, Ludmila, Gross, Nicole E., Charmsaz, Soren, Xavier, Stephanie, Leatherman, James, Wang, Hao, Yarchoan, Mark, Jaffee, Elizabeth M., Fertig, Elana J., Ho, Won Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9675468/
https://www.ncbi.nlm.nih.gov/pubmed/36214223
http://dx.doi.org/10.1172/jci.insight.160398
_version_ 1784833380259463168
author Sidiropoulos, Dimitrios N.
Stein-O’Brien, Genevieve L.
Danilova, Ludmila
Gross, Nicole E.
Charmsaz, Soren
Xavier, Stephanie
Leatherman, James
Wang, Hao
Yarchoan, Mark
Jaffee, Elizabeth M.
Fertig, Elana J.
Ho, Won Jin
author_facet Sidiropoulos, Dimitrios N.
Stein-O’Brien, Genevieve L.
Danilova, Ludmila
Gross, Nicole E.
Charmsaz, Soren
Xavier, Stephanie
Leatherman, James
Wang, Hao
Yarchoan, Mark
Jaffee, Elizabeth M.
Fertig, Elana J.
Ho, Won Jin
author_sort Sidiropoulos, Dimitrios N.
collection PubMed
description Mass cytometry, or cytometry by TOF (CyTOF), provides a robust means of determining protein-level measurements of more than 40 markers simultaneously. While the functional states of immune cells occur along continuous phenotypic transitions, cytometric studies surveying cell phenotypes often rely on static metrics, such as discrete cell-type abundances, based on canonical markers and/or restrictive gating strategies. To overcome this limitation, we applied single-cell trajectory inference and nonnegative matrix factorization methods to CyTOF data to trace the dynamics of T cell states. In the setting of cancer immunotherapy, we showed that patient-specific summaries of continuous phenotypic shifts in T cells could be inferred from peripheral blood–derived CyTOF mass cytometry data. We further illustrated that transfer learning enabled these T cell continuous metrics to be used to estimate patient-specific cell states in new sample cohorts from a reference patient data set. Our work establishes the utility of continuous metrics for CyTOF analysis as tools for translational discovery.
format Online
Article
Text
id pubmed-9675468
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Society for Clinical Investigation
record_format MEDLINE/PubMed
spelling pubmed-96754682022-11-21 Integrated T cell cytometry metrics for immune-monitoring applications in immunotherapy clinical trials Sidiropoulos, Dimitrios N. Stein-O’Brien, Genevieve L. Danilova, Ludmila Gross, Nicole E. Charmsaz, Soren Xavier, Stephanie Leatherman, James Wang, Hao Yarchoan, Mark Jaffee, Elizabeth M. Fertig, Elana J. Ho, Won Jin JCI Insight Technical Advance Mass cytometry, or cytometry by TOF (CyTOF), provides a robust means of determining protein-level measurements of more than 40 markers simultaneously. While the functional states of immune cells occur along continuous phenotypic transitions, cytometric studies surveying cell phenotypes often rely on static metrics, such as discrete cell-type abundances, based on canonical markers and/or restrictive gating strategies. To overcome this limitation, we applied single-cell trajectory inference and nonnegative matrix factorization methods to CyTOF data to trace the dynamics of T cell states. In the setting of cancer immunotherapy, we showed that patient-specific summaries of continuous phenotypic shifts in T cells could be inferred from peripheral blood–derived CyTOF mass cytometry data. We further illustrated that transfer learning enabled these T cell continuous metrics to be used to estimate patient-specific cell states in new sample cohorts from a reference patient data set. Our work establishes the utility of continuous metrics for CyTOF analysis as tools for translational discovery. American Society for Clinical Investigation 2022-10-10 /pmc/articles/PMC9675468/ /pubmed/36214223 http://dx.doi.org/10.1172/jci.insight.160398 Text en © 2022 Sidiropoulos et al. https://creativecommons.org/licenses/by/4.0/This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Technical Advance
Sidiropoulos, Dimitrios N.
Stein-O’Brien, Genevieve L.
Danilova, Ludmila
Gross, Nicole E.
Charmsaz, Soren
Xavier, Stephanie
Leatherman, James
Wang, Hao
Yarchoan, Mark
Jaffee, Elizabeth M.
Fertig, Elana J.
Ho, Won Jin
Integrated T cell cytometry metrics for immune-monitoring applications in immunotherapy clinical trials
title Integrated T cell cytometry metrics for immune-monitoring applications in immunotherapy clinical trials
title_full Integrated T cell cytometry metrics for immune-monitoring applications in immunotherapy clinical trials
title_fullStr Integrated T cell cytometry metrics for immune-monitoring applications in immunotherapy clinical trials
title_full_unstemmed Integrated T cell cytometry metrics for immune-monitoring applications in immunotherapy clinical trials
title_short Integrated T cell cytometry metrics for immune-monitoring applications in immunotherapy clinical trials
title_sort integrated t cell cytometry metrics for immune-monitoring applications in immunotherapy clinical trials
topic Technical Advance
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9675468/
https://www.ncbi.nlm.nih.gov/pubmed/36214223
http://dx.doi.org/10.1172/jci.insight.160398
work_keys_str_mv AT sidiropoulosdimitriosn integratedtcellcytometrymetricsforimmunemonitoringapplicationsinimmunotherapyclinicaltrials
AT steinobriengenevievel integratedtcellcytometrymetricsforimmunemonitoringapplicationsinimmunotherapyclinicaltrials
AT danilovaludmila integratedtcellcytometrymetricsforimmunemonitoringapplicationsinimmunotherapyclinicaltrials
AT grossnicolee integratedtcellcytometrymetricsforimmunemonitoringapplicationsinimmunotherapyclinicaltrials
AT charmsazsoren integratedtcellcytometrymetricsforimmunemonitoringapplicationsinimmunotherapyclinicaltrials
AT xavierstephanie integratedtcellcytometrymetricsforimmunemonitoringapplicationsinimmunotherapyclinicaltrials
AT leathermanjames integratedtcellcytometrymetricsforimmunemonitoringapplicationsinimmunotherapyclinicaltrials
AT wanghao integratedtcellcytometrymetricsforimmunemonitoringapplicationsinimmunotherapyclinicaltrials
AT yarchoanmark integratedtcellcytometrymetricsforimmunemonitoringapplicationsinimmunotherapyclinicaltrials
AT jaffeeelizabethm integratedtcellcytometrymetricsforimmunemonitoringapplicationsinimmunotherapyclinicaltrials
AT fertigelanaj integratedtcellcytometrymetricsforimmunemonitoringapplicationsinimmunotherapyclinicaltrials
AT howonjin integratedtcellcytometrymetricsforimmunemonitoringapplicationsinimmunotherapyclinicaltrials